

# An-An Yin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3299865/publications.pdf>

Version: 2024-02-01

15  
papers

341  
citations

840728

11  
h-index

1058452

14  
g-index

16  
all docs

16  
docs citations

16  
times ranked

615  
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiotherapy Plus Concurrent or Sequential Temozolomide for Glioblastoma in the Elderly: A Meta-Analysis. PLoS ONE, 2013, 8, e74242.	2.5	55
2	The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in Elderly Glioblastoma Patients: A Meta-Analysis. PLoS ONE, 2014, 9, e85102.	2.5	38
3	A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. Journal of Neuro-Oncology, 2014, 116, 315-324.	2.9	38
4	The treatment of glioblastomas: A systematic update on clinical Phase III trials. Critical Reviews in Oncology/Hematology, 2013, 87, 265-282.	4.4	32
5	Risks and benefits of stress ulcer prophylaxis in adult neurocritical care patients: a systematic review and meta-analysis of randomized controlled trials. Critical Care, 2015, 19, 409.	5.8	31
6	A novel prognostic six CpG signature in glioblastomas. CNS Neuroscience and Therapeutics, 2018, 24, 167-177.	3.9	30
7	Saponin 1 Induces Apoptosis and Suppresses NF- $\kappa$ B-Mediated Survival Signaling in Glioblastoma Multiforme (GBM). PLoS ONE, 2013, 8, e81258.	2.5	24
8	Resveratrol suppresses human glioblastoma cell migration and invasion via activation of RhoA/ROCK signaling pathway. Oncology Letters, 2016, 11, 484-490.	1.8	20
9	Integrative analysis of novel hypomethylation and gene expression signatures in glioblastomas. Oncotarget, 2017, 8, 89607-89619.	1.8	19
10	Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas. Clinical Epigenetics, 2019, 11, 76.	4.1	14
11	Dec1 expression predicts prognosis and the response to temozolomide chemotherapy in patients with glioma. Molecular Medicine Reports, 2016, 14, 5626-5636.	2.4	12
12	A five CpG signature of microRNA methylation in non-G-CIMP glioblastoma. CNS Neuroscience and Therapeutics, 2019, 25, 937-950.	3.9	12
13	Integrative analysis identifies an immune-relevant epigenetic signature for prognostication of non-G-CIMP glioblastomas. Oncoimmunology, 2021, 10, 1902071.	4.6	8
14	New way to achieve frontal facial photographs of the head in its natural position. British Journal of Oral and Maxillofacial Surgery, 2014, 52, 563-565.	0.8	7
15	A Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP Glioblastomas. Journal of Oncology, 2022, 2022, 1-15.	1.3	1